Dendreon: Bear Trap of the Year 8 comments
April 30, 2009
| about: DNDN
-
Font Size:
-
Print
- TweetThis
Related Articles
|
Related Articles
|
This article has 8 comments:
"Expect Massive BEAR RAID this afternoon @ 12 30 pm central last trade 24 suggest you sell short into strength MASSIVE BEAR RAID coming.. TODAY "
And then a little later, this....
"u should be positioning on the short side of DNDN right now at 24 and on any additional strength ahead of conference by 12 30 stock will be in the throes of a MASSIVE BEAR RAID smart $ has a BIG surprise for the eager buyers if you wanted to own DNDN plenty of shares were avail last month for 3 bux NOW u should be piling on the short side I reiterate..
MASSIVE BEAR RAID TODAY 12 30 pm central"
So apparently this type of thing can be predicted if you look for the right signs.
The wild price fluctuation is criminal
On Apr 30 01:32 PM foofighter wrote:
> It was interesting to see this on the DNDN yahoo message board prior
> to the dip...
>
> "Expect Massive BEAR RAID this afternoon @ 12 30 pm central last
> trade 24 suggest you sell short into strength MASSIVE BEAR RAID coming..
> TODAY "
>
> And then a little later, this....
>
> "u should be positioning on the short side of DNDN right now at 24
> and on any additional strength ahead of conference by 12 30 stock
> will be in the throes of a MASSIVE BEAR RAID smart $ has a BIG surprise
> for the eager buyers if you wanted to own DNDN plenty of shares were
> avail last month for 3 bux NOW u should be piling on the short side
> I reiterate..
> MASSIVE BEAR RAID TODAY 12 30 pm central"
>
> So apparently this type of thing can be predicted if you look for
> the right signs.
Dendreon (DNDN) shares more than led on April 14, and have risen more than 1000% in the last six weeks, after the company said its cancer drug, Provenge, met a late-stage study goal, strongly boosting chances of FDA approval. While investors were busy piling into the shares, two executives took $1.9M in profit off the table. On April 20, Principal Accounting Officer Greg Cox exercised 15,313 shares and ultimately sold the shares for $306,260, or $20 a share, for a profit of $189,998. Cox also sold 2,168 shares for $43,360, or $20 a share. On April 14, director Gerardo Canet exercised 109,171 shares and ultimately sold the shares for $2.3M, or $21.40 a share, for a profit of $1.6M. He continues to own 20,956 shares directly. Neither of the insiders owns more than 1% of Dendreon shares outstanding. The transactions were made through 10b5-1 trading plans. It was Cox's first sale of stock and Canet's second, after a small 2007 sale. Only five insiders have sold since 2000. Lon Juricic, president of StreetInsider.com says that he can't blame the insiders for taking some of their money out of the game at this point. Juricic believes the shares will likely hang around the $20 range until more material news about Provenge's FDA approval emerges
I think with the volatility of the stock and the success of Provenge, the Company should sell itself to take the volatility out of the stock price and stabilize the future of their promising therapies. I can't blame them for cashing out some of their options, but they should consider the position of the long term backers of this still somewhat fragile Company..